EyeGene Inc. | Balance Sheet

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
Cash & Short Term Investments
5,826
4,586
23,287
12,890
24,508
Total Accounts Receivable
84
112
222
319
314
Other Current Assets
-
3
10
1
4
Total Current Assets
5,913
4,698
23,519
13,210
24,827
Net Property, Plant & Equipment
28
323
337
1,559
1,322
Total Investments and Advances
53
202
156
2,808
3,061
Intangible Assets
293
320
316
414
502
Other Assets
28
-
-
565
573
Total Assets
6,315
5,543
24,328
18,557
30,284
Other Current Liabilities
706
995
1,075
1,163
1,249
Total Current Liabilities
706
995
1,075
1,163
1,249
Long-Term Debt
-
-
-
-
3,788
Provision for Risks & Charges
231
344
384
1,017
1,240
Other Liabilities
306
351
-
-
-
Total Liabilities
1,242
1,689
1,459
2,181
6,278
Common Equity (Total)
5,073
3,854
22,763
16,185
23,753
Total Shareholders' Equity
5,073
3,854
22,763
16,185
23,753
Total Equity
5,073
3,854
22,763
16,185
23,753
Liabilities & Shareholders' Equity
6,315
5,543
24,328
18,557
30,284
Non-Equity Reserves
-
-
106
191
253

About EyeGene

View Profile
Address
Unit 910, Gangseo Han-gang Zai B
Seoul SL 07528
Korea, Republic Of
Employees -
Website http://www.eyegene.co.kr
Updated 09/14/2018
Eyegene, Inc. engages in the research and development of pharmaceutical products. Its products include curing technologies and vaccines for diabetic retinopathy, decubitus ulcer, cervical cancer, and adjuvant immunotherapy. The company was founded on June 23, 2000 and is headquartered in Seoul, South Korea.